THERAPEUTIC NUCLEOSIDES

Abstract: The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment and prophylaxis of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.

Description: Therapeutic Nucleosides The present invention relates to purine nucleoside analogues containing an unsaturated carbocyclic ring in place of the sugar residue, pharmaceutically acceptable derivatives thereof, and their use in therapy, particularly for the treatment or prophylaxis of certain viral infections. AIDS is an immunosuppressive or iπtmunodestructive disease that predis¬ poses subjects to fatal opportunistic infections. Characteristically, AIDS is associated with a progressive depletion of T-cells, especially 4 the helper-inducer subset bearing the OKT surface marker. Human Immunodeficiency Virus (HIV) has been reproducibly isolated from patients with AIDS or with the symptoms that frequently precede AIDS. HIV is cytopathic and appears to preferentially infect and destroy 4 T-cells bearing the OKT marker , and it is now generally recognized that HIV is the etiological agent of AIDS. Since the discovery that HIV is the etiological agent of AIDS, numerous proposals have been made for anti-HIV che otherapeutic agents that may be effective in treating AIDS sufferers. Thus, for example, Europea... Patent Specification No. 196185 describes 3' -azido-3' -deoxythymidine (which has the approved name zidovudine) , its pharmaceutically accept¬ able derivatives and their use in the treatment of human retrovirus infections including AIDS and associated clinical conditions. Vince et al., Antiviral Research, £ (1/2), 120 (1988) describes certain carbocy¬ clic purine nucleosides and their use against HIV. At the Second International Conference on antiviral research Williamsburg VA, 10/14 April 1988, (±)-9-(cis-4-(hydroxymethyl -2-cyclopentenyl) guanine (NSC - 614846), also known as carbovir, was disclosed. World wide, hepatitis B (HBV) is a viral pathogen of major consequence. It is most common in Asian countries, and prevalent in sub-Sahara Africa. The virus is aetiologically associated with primary hepato- S U B ST ITUTESHEET cellular carcinoma and is thought to cause 80% of the world's liver cancer. In the United States more than ten thousand people are hospitalised for HBV illness each year, an average of 250 die with fulminant disease. The United States currently contains an estimated pool of 500,000-1-million infectious carriers. Chronic active hepatitis will develop in over 25% of carriers, and often progresses to cirrhosis. It is estimated that 5000 people die from HBV related cirrhosis each year in the USA, and that perhaps 1000 die from HBV-related liver cancer. Even when a universal HBV vaccine is in place, the need for effective anti-HBV compounds will continue. The large reservoir of persistently infected carriers, estimated at 220 million worldwide, will receive no benefit from vaccination and will continue at high risk for HBV induced liver disease. This carrier population serves as the source of infection of susceptible individuals perpetuating the instance of disease particularly in endemic areas or high risk groups such as IV drug abusers and homosexuals. Thus, there is a great need for effective antiviral agents, both to control the chronic infection and reduce progression to hepatocellular carcinoma. Clinical effects of infection with the HBV virus range from headache, fever, malaise, nausea, vomiting, anorexia and abdominal pains. Replication of the virus is usually controlled by the immune response, with a course of recovery lasting weeks or months in humans, but infection may be more severe leading to persistent chronic liver disease as outlined above. In "Viral Infections of Humans" (second edition, Ed., Evans, A.S. (1982) Plenum Publishing Corporation, New York), Chapter 12 describes in some detail, the aetiology of viral hepatitis infections. Hepatitis B virus (HBV) is a small DNA containing virus which infects humans. It is a member of the class of closely related viruses known as the hepadnaviruses, each member of which selectively infects either mammalian or avian hosts, such as the woodchuck and the duck. Recent insights into the mechanism of replication of the hepadnavirus genome SUBSTITUTE SHEET by reverse transcription of an RNA intermediate, suggests that this reverse transcriptase is a logical chemotherapeutic target. It has now been discovered that certain purine nucleoside analogues containing an unsaturated carbocyclic ring, as referred to below, are useful for the treatment or prophylaxis of viral infections for example hepatitis B infections, and retroviral infections, especially AIDS. According to a feature of the present invention, novel compounds of the formula (I) are provided: wherein R represents 3. represents cycloalkenyloxy; or 4-! R represents J k -i cycloalkenylthio; or R represents an amino group which is mono substituted by any one of C branched or straight chain alkyl optionally substituted by one or more amino groups or alkylamino groups; C„ g cycloalkenyl (e.g. cyclopenten-1-yl) ; C. , hydroxyalkyl (e.g. hydroxymethyl) ; C alkyl substituted by C_ cycloalkyl; or R SUBSTITUTE SHEET represents an amino group which is di-substituted by any one substituent selected from C- _ branched or straight chain alkyl l-o optionally substituted by one or more amino groups, alkylamino groups or C. fi alkoxy groups; C . cycloalkenyl; C- , hydroxyalkyl; C, - alkyl substituted by C_ fi cycloalkyl and any one substituent selected from C. , alkyl (e.g. methyl or ethyl); c - . c hydroxyalkyl (e.g. hydroxyethyl) ; C, „ cycloalkyl (preferably C, -_ cycloalkyl, e.g. cyclopropyl, cyclobutyl or cyclopentyl) optionally substituted by C. - i-6 alkyl (e.g. methylcyclopropyl) or aryl (e.g. phenylcyclopropyl); aryl (e.g. phenyl) or aralkyl (e.g. benzyl) in which the aryl may optionally be substituted with C. , alkyl, hydroxy or halogen; allyl optionally substituted with mono- or di-alkyl or alkoxy groups (e.g. 3 dimethylallyl) ; and R represents hydrogen, amino, C. - alkyl (e.g. methyl), or thio optionally substituted by C. - alkyl; provided that 1 3 2 when R is A and R is hydrogen or C. , alkyl, R is not an amino group substituted by a single C, _ cycloalkyl and hydrogen or a branched or straight chain C. , alkyl; or a pharmaceutically acceptable derivative thereof. Preferred examples of compounds of formula (I) include those wherein R represents A. The most preferred isomers are those in which the hydroxymethyl group is cis to the purine in compounds of formula (I) . It is to be understood that the present invention encompasses the individual enantiomers of the compounds of formula (I) as well as wholly or partially racemic mixtures of such enantiomers even though the precise structures as drawn relate to one enantiomer. The compounds of formula (I) above and their pharmaceutically acceptable derivatives are hereinafter referred to as the compounds according to the invention. In one aspect of the invention there are provided the compounds according to the invention for use in medical therapy particularly for SUBSTITUTE SHEET the treatment or prophylaxis of retroviral infections and heptatis B infections. Examples of retroviral infections which may be treated or prevented in accordance with the invention include human retroviral infections such as Human Immunodeficiency Virus (HIV), HIV-1 or HIV-2 and Human T-cell Lymphotropic Virus (TL) e.g. HTLV-I or HTLV-II infections. The compounds according to the invention are especially useful for the treatment or prophylaxis of AIDS and related clincial conditions such as AIDS-related complex (ARC) , progressive generalised lymphadenopathy (PGL) , AIDS-related neurological conditions, such as multiple sclerosis or tropical paraparesis, anti-HIV antibody-positive and HIV-positive conditions, Kaposi's sarcoma and thrombocytopenia purpura. The compounds may also be used in the treatment or prevention of psoriasis. The compounds of the present invention are particularly applicable for the treatment of asymptomatic infections or diseases in humans caused by or associated with human retroviruses. In a further aspect of the present invention there is included:- a) A method for the treatment or prophylaxis of retroviral infections and hepatitis B infections which comprises treating the subject with a therapeutically effective amount of a compound according to the invention. b) Use of a compound according to the invention in the manufacture of a medicament for the treatment or prophylaxis of any of the above-mentioned infections or conditions. By "a pharmaceutically acceptable derivative" is meant any pharmaceut¬ ically acceptable salt, ester, or salt of such ester, or ether, of compound according to the invention or any other compound which, upo administration to the recipient, is capable of providing (directly o SUBSTITUTE SHEET indirectly) a compound according to the invention, or an antivirally active metabolite or residue thereof. Preferred esters of the compounds of the invention include carboxylic acid esters in which the non-carbonyl moiety of the este.. grouping is selected from straight or branched chain alkyl e.g. n-propyl, t-butyl, n-butyl, alkoxyalkyl (e.g. methoxymethyl) , aralkyl (e.g. benzyl), aryloxyalkyl (e.g. phenoxymethyl) , aryl (e.g. phenyl optionally substituted by halogen, C- , alkyl or C- , alkoxy) ; sulphonate esters such as alkyl- or aralkylsulphonyl (e.g. methanesulphonyl) ; amino acid esters (e.g. L-valyl or L-isoleucyl) ; and mono-, di- or tri-phosphate esters. The phosphate esters may be further esterified by, for example, a C „ alcohol or a reactive derivative thereof, or by a 2,3-di(C, „, )arylglycerol. With regard to the above-described esters, unless otherwise specified, any alkyl moiety present advantageously contains 1 to 18 carbon atoms, particularly 1 to 4 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group. Any reference to any of the above compounds also includes a reference to a pharmaceutically acceptable salt thereof. Examples of pharmaceutically acceptable salts of the compounds according to the invention and pharmaceutically acceptable derivatives thereof include base salts, eg derived from an appropriate base, such as alkali metal (e.g. sodium), alkaline earth metal (e.g. magnesium) salts, ammonium and NW, (wherein W is C. alkyl). Physiologically acceptable salts of a hydrogen atom or an amino group include salts of organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids and inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids. Physiologically acceptable salts of a compound with a hydroxy group include the anion of said SUBSTITUTESHEET + + compound in combination with a suitable cation such as Na , NH, , and _4_ N7, (wherein W is a C. , alkyl group) . The above compounds according to the invention and their pharmaceut¬ ically acceptable derivatives may be employed in combination with other therapeutic agents f r the treatment or prophylaxis of the above infections or conditions. Examples of such further therapeutic agents include agents that are effective for the treatment or prophylaxis of viral infections or associated conditions such as 3' -azido-3' -deoxy- thymidine (zidovudine) , 2' ,3' -dideoxynucleosides such as 2' ,3' -dideoxy- cytidine, 2' ,3' -dideoxy adenosine and 2' ,3' -dideoxyinosine, acyclic nucleosides (eg acyclovir) , interferons such as α-interferon, renal excretion inhibitors such as probenicid, nucleoside transport inhibit¬ ors such as dipyridamole, dialzep, mio-, lido- or foluflazine or hexobendine as well as immunomodulators such as interleukin II and granulocyte acrophage colony stimulating factors, soluble CD or genetically engineered derivatives thereof, and phosphonoformic acid. The component compounds of such combination therapy may be administered simultaneously, in either separate or combined formulations, or at different times, e.g. sequentially such that a combined effect is achieved. The compounds according to the invention, also referred to herein as the active ingredient, may be administered for therapy by any suitable route including oral, rectal, nasal, topical (including buccal and sublingual) , vaginal and parenteral (including subcutaneous, intramus¬ cular, intravenous and intradermal) . It will be appreciated that the preferred route will vary with the condition and age of the recipient, the nature of the infection and the chosen active ingredient. In general a suitable dose will be in the range of 3.0 to 120 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg per kilogram body weight per day and most preferably in the range 15 to 60 mg per kilogram body weight per day. The desired dose is preferably presented as two, three, four, five, six or more SUBSTITUTESHEET sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 10 to 1500 mg, preferably 20 to 1000 mg, and most preferably 50 to 700 mg of active ingredient per unit dosage form. Ideally, the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 1 to about 75μM, preferably about 2 to 50μM, most preferably about 3 to about 30μM. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1 to about 100 mg/kg of the active ingredient. Desirable blood levels may be maintained by a continuous infusion to provide about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient. While it is possible for the active ingredient to be administered alone it is preferable to present it as a pharmaceutical formulation. The formulations of the present invention comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof and optionally other therapeutic agents. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual) , vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) adminis¬ tration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product. SUBSTITUTESHEET Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water- in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste. A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as a powder or granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lub¬ ricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach. This is particularly advantageous for purine nucleoside derivatives as such compounds are susceptible to acid hydrolysis. Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usuall sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucros and acacia; and mouthwashes comprising the active ingredient in suitable liquid carrier. S U BSTITUTESHEET Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate. Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate. Formulations suitable for parenteral administration include aqueous and non- aqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspen¬ ding agents and thickening agents. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient. The compounds according to the invention may also be presented for use in the form of veterinary formulations, which may be prepared, for example, by methods that are conventional in the art. It should be understood that in addition to the ingredients particu¬ larly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral adminis- SUBSTITUTESHEET tration may include such further agents as sweeteners, thickeners and flavouring agents. The present invention further includes a process for the preparation of a compound according to the invention and pharmaceutically acceptable derivatives thereof which comprises either: A) treating a compound of formula wherein R is as hereinbefore defined and Z represents a precursor 2 group for the said R group with an agent or under conditions serving 2 to convert the precursor Z group to the desired R group) ; or Z represents a thio group onto which may be substituted an appropriate 2 group to form a compound of formula (I) wherein R is a substituted thio group or; B) reacting a compound of formula (wherein R an are ere n e ore e ne or a p armaceutically acceptable derivative thereof, with an agent serving to effect formation of the imidazole ring in the desired compound of formula (I); or SUBSTITUTESHEET i) where a compound of formula (I) is formed, converting the said compound to a pharmaceutically acceptable derivative thereof; or ii) where a pharmaceutically acceptable derivative of a compound of formula (I) is formed, converting the said derivative to the parent compound of formula (I) or to a further such derivative. Process A) above may be carried out in conventional manner, for example, by treatment of a compound of formula (II) in which Z represents a leaving group, e.g. a halo such as a chloro group, with, for example, an alkali metal (e.g. sodium) or alkali metal hydride (e.g. sodium hydride) and an appropriate alcohol at reflux or a temperature greater than 50 C preferably in an organic solvent. Alternatively the compound of formula (II) may be treated with an appropriate amine or amino hydrochloride to introduce a substituted amino group as defined above at reflux or at a temperature greater than 50 C preferably in the presence of an organic solvent, for example methanol, ethanol. Alternatively, a compound of formula (II) wherein Z is a thio group may be treated with an appropriate halide or halo under nitr:.; ->n. Process B) may be carried out, e.g., by reacting a compound of formula (III) with formic acid or a reactive formic acid derivative, triethyl orthoformate or diethoxymethyl acetate, in a solvent such as a di- methylacetamide or acetonitrile at an elevated temperature, preferably at 75-90 C. This reaction is conveniently effected by the addition of slightly more than one equivalent of a strong anhydrous acid, with 1.1 equivalents of ethanesulfonic acid per equivalent of compound of formula (III), in which case lower temperatures, 25 C, are used. SUBSTITUTE SHEET In process A) the starting material of formula (II) may be prepared, for example, by firstly cyclising a compound of formula (III) above in an analogous manner to that described for process B) above. Alterna¬ tively, (+)-9-(cis-4-(hydroxymethyl)-2-cyclopentenyl)guanine prepared e.g. as described in AU-A-28671/89 incorporated herein by reference from aristeromycin, may be converted to compounds of formula (I) . Other reagents may be useful for cyclisation of compounds of formula 3 (III) to give compounds of formula (I) where R is not hydrogen. For example triethyl or trimethylorthoacetate with acetic anhydride at 70-120 C for several hours gives R -CH_ (see H.C. Koppel and R.K. 3 Robins, J.Org.Chem. 1958, 1457), R =NH„ may be obtained by cylisation with ethoxycarbonyl isothiocyanate (see R. Esmail and F.Kurzer, Synthesis 1975. 301; L.B.Towsend, et al., J.Heterocyclic Chem. 1984. 3 21. 1245). This initially gives R =NHC_ Et which is then hydrolysed in 3 base (e.g. aqueous sodium hydroxide) to R =NH„. Cyclisation with potassium ethylanthate (W.T. Stolle, J.C. Sih, R.S.P. Hsi, J. Lable. Compound Radiopharm. 1988. 891) in ethanol at 80°C gives R -SH. Alkylation of the SH with alkyl halides and base (e.g. potassium 3 carbonate in DMF) gives R =SMe, SEt. A compound of formula (I) may be converted into a pharmaceutically acceptable ester by reaction wi h an appropriate esterifying agent, e.g. an acid halide or anhydride. The compound of formula (I), including esters thereof, may be converted into pharmaceutically acceptable salts thereof in conventional manner, e.g. by treatment with an appropriate acid. An ester or salt of a compound of formula (I) may be converted into the parent compound, e.g. by hydrolysis. The enantiomers of the compounds of formula (I) may be resolved or isolated in conventional manner, e.g. by chromatographic separation or diastereomeric esters prepared by acylation of the hydroxyl on the cyclopentenyl moiety with appropriate optically active carboxylic acid derivatives as, e.g., with naproxen (J.Org.Chem. , 51, 1287 (1986)). The cyclopentenyl precursors of the compounds of formula (III) , may SUBSTITUTE SHEET also be resolved by fractional crystallization of salts formed with optically active carboxylic acids (e.g. di-benzoyl-D-tartaric acid and its derivatives) . Alternatively, enzymatic resolution may be achieved as in J.Med.Che . , 30, 746 (1987) and J.Med.Chem. 28, 1385 (1985). The following Examples are intended for illustration only and are not intended to limit the scope of the invention in any way. The term 'active ingredient' as used in the Examples means a compound of formula (I) or a pharmaceutically acceptable derivative thereof. Example 1 (±) -cis-4-T(2-Amino-4-chloro-6-nyrimidinyl ' )amino1 -2-cvclopentene-l- methanol cis-4-Acetamidocyclopent-2-enemethyl acetate [S.Daluge and R.Vince, J.Or .Chem. 1978. 43, 2311] (14.88g, 0.73mol) and barium hydroxide octahydrate (46.19g, 0.146 mol) were refluxed in water (300mL) under nitrogen for 18 hours. The resulting solution was neutralized with carbon dioxide. The precipitate was washed with water, then ethanol. The combined filtrate-wash was evaporated to a syrup (11.16g) which was condensed with 2-amino-4,6-dichloropyrimidine (23.91g, 0.146mol) and triethylamine (30.5mL, 0.219mol) in refluxing 1-butanol (lOOmL) for 1.5 hours. After addition of IN NaOH (73mL) , the resulting mixf-re was evaporated to dryness and the residual solid slurried in CHC1_ (200mL) . Unreacted 2-amino-4,6-dichloropyrimidine was filtered off and washed with chloroform (lOOmL) . The chloroform filtrate-wash was concentrated and chromatographed on a silica gel column. Additional pyrimidine starting material was eluted with 2.5% methanol-chloroform. The title compound was eluted with 3.5% methanol-chloroform as an off-white solid foam (15.90g, 91%); 'H-NMR ( e^O-dg) 1.15-1.28 and 2.26-2.41 (2m,2,CH 2 ), 2.60-2.71 (m,l,l'-H), 3.4 (m overlapping H 2 0, CH OH) , 4.625 (t,J-=5.3,l,CH 2 OH), 4.95 (br s.l.CH-K), 5.67-5.87 (m,2,CH-CH) , 6.38 (br s,l,NH 2 ), 7.12(br s.l.NH); MS (CP)M+1,241,243_ SUBSTITUTE SHEE Anal. calc. for .0.2H 2 0: C.48.99; H.5.55; N.22.85; Cl,14.46. Found: C.49.10; H,5.57; N.22.81; Cl,14.40. Example 2 (±)-cis-4- T r2-Amino-6-chloro-5- . (4-chlorophenyl)azol-4-pyrimidinyll - amino1-2-cvclopentene-1-methanol (±)-cis-4- [ (2-Amino-4-chloro-6-pyrimidinyl)amino] -2-cyclopentene-l- methanol from Example 1 (11.58g, 48.1mmol) and sodium acetate trihydrate (97g) was dissolved in glacial acetic acid (225mL) and water (225mL) . A cold solution (0.5 C) of 4-chlorobenzenediazonium chloride was prepared from 4-chloroaniline (6.74g, 52.8mol), concentrated hydrochloric acid (14.7mL) water (52mL) , and sodium nitrite (4.01g, 58.2mMol in 47mL of water). This cold solution was added dropwise over 5 minutes to the first solution. The resulting yellow precipitate was filtered after 18 hours, washed with water, and extracted with ethanol to give title compound as dark yellow powder (12.56g, 69%), Mp 218-220°C dec; 'H-NMR ( e^O-dg) 10.25 (d.l.NH), 7.69 and 7.54 (both, J=8.9,C 6 H 4 overlapping 7.6 (br,6,NH 2 ), 5.80-5.95 (m,2,CH-CH) 5.24 (m . l.CHN), 4.75 (t,1,CH j OH) , 3.41 (t.l.C^OH), 3.41 (t,2,CH 2 OH), 2.75 (m,l,CH), 2.41 (m.l.CH), 1.44-1.53 (m.l.CH). Anal calc. for C..H_. ,.N r Cl 0: C, 50.67; H.4.25; N.22.16; Cl.18.70. lb lb b __. Found: C,50.49; H,4.29; N.22.10; Cl.18.66 Example 3 (±)-cis-4- r (2.5-Diamino-4-chloro-6-pyrimidinyl ' -amino1 -2-cyclopen- tene-1-methanol The title compound of Example 2 (11.67g) was suspended in ethanol (235mL) , glacial acetic acid (30mL) , and water 235mL) . The mixture was heated to reflux under nitrogen. Zinc dust (13.5g) was added in small portions over 30 minutes during which time the compound dissolved. The reaction was heated an additional 20 minutes, and then the excess zinc was filtered off from the hot solution, and it was washed with ethanol. SUBSTITUTESHEET The filtrates were evaporated, and the residue was purified on a silica gel column eluting with chloroform (1L) and chloroform:methanol/4:l (1.8L). The fractions containing the product were combined, and the solvent was removed under reduced pressure to give the title compound as a red-orange oil (11.2g, >100% yield). A pure sample was obtained during another small scale reaction to obtain the product as a light yellow solid in a 76% yield; 1 H-NMR ( e^O-dg) 1.29 and 2.39 (m,2,CH 2 ), 2.69 (6,1,1'-H), 3.37 (d,2,CH 2 OH), 3.91 (br,2,NH 2 ), 4.60 (br,1,CH 2 0H) , 5.02 (m.l.CHNH), 5.56 (br,s,2,NH 2 ) , 5.74 (m.l.-CH), 5.86 (m,l,-CH) , 6.36 (d,l,CHNH). Example 4 (±)-cis-4-(2-Amino-6-chloro-9H-purin-9-yl')-2-cvclopentene-l-methanol The title compound of Example 3 (about 9.7g) was dissolved in diethoxy- methyl acetate (lOOg) , and refluxed for two days. The solvent was removed under high vacuum at 50 C, and dioxane (40mL) and 0.5N HC1 (60mL) was added. The reaction was stirred at room temperature for 1.25 hours, and then chilled. The reaction was neutralized to pH7 with -V.*, cold 5N sodium hydroxide, and then it was extracted with chloroform: methanol/3:l several times. The organic layers were dried with magnesium sulphate, filtered, and evaporated. The residue was purified by chromatography on a silica gel column, eluting with CHC1,:2% MeOH/CHCl to give 3.7g (46% yield) of the title compound, Mp 13R-139°C. 1 H-NMR Me^O-dg) 1.63 and 2.61 (πt,2.CH 2 ), 2.87 (m.l.l'-H), 3.44 (d,2,CH 2 OH), 5.44 (m,l,CH-N), 5.89 (m,l,=CH), 6.14 (m.l-CH), 6.82 (br s,2,NH 2 ), 8.02 (s,l,8-H). CH 2 0H not seen - under H 2 0 peak) uv: pH 1 lambda max 315 (7370), 218 (26200); lambda sh 239.5 (5650). pH 7.4 lambda max 307 (8000), 245.5 (4600), 223 (26400). MS (El) 265,267 (m) (Cl) 266,268 (m + 1) . Anal. Calc. for C-^H-^N^CIO^^O: C.43.79; H.5.35; N.23.21; Cl.11,75. Found: C.43.67; H.5.29; N.23.05; Cl.11.70 Example 5 (±)-cis-2-Amino-l.9-dihydro-9- r(4-hydroxymethyl)-2-cyclopenten-l-yll - 6H-purin-6-thione (+)-cis-4-(2-Amino-6-chloro-9H-purin-9-yl)-2-cyclopenten-1-methanol (4.18g,15.7mmol) from Example 4 and thiourea (1.32g,17.3mmol) were refluxed in n-propanol for 17 hours. The resulting mixture was filtered and the solid washed with n-propanol to give (+)-cis-2-amino, 1,9-dihydro-9- [ (4-hydroxymethyl)-2-cyclopenten-1-yl)-6H-purin-6-thione as yellow powder (2.19g,53%); Mp 235-238°C, Η-NMR(DMSO-d g ) δ; 11.85 (5.1.NH); 7.77 (s,l,H-8), 6.76 (br s,2,NH 2 ), 6.16 and 5.86 (both m,2,CH-CH), 5.35 (m.l.CH-N), 4.70 (m.l.OH), 3.42 (br m, overlapping H 0,CH 2 -0), 2.85 (br m.l.CH), 2.30 (m, overlapping solvent, 0.5 CH ) , 1.60 (m,l,0.5,CH 2 ). Anal. calc. for C^H^N OS: C.50.18; H.4.98; N.26.60; S.12.18. Found: C.50.10; H.5.00; N.26.50; S.12.10 Example 6 (±)-cis-4- (2-Amino-6-(2-cyclohexen-l-yl ' . thio'. -9H-purin-9-yl ' )-2-cyclo¬ penten-1-me hanol To a solution of (+) -cis-2-amino-l,9-dihydro-9- [ (4-hydroxymethyl)-2- cyclopenten-1-yl] -6H-purin-6-thione (0.50g, 1.89mMol) from Example 5 in IN NaOH (1.89ml) was added 3-bromocyclohexene (0.305g, 1.89mMol) and dioxane (2mL) . The solution was stirred under nitrogen for 2 hours and extracted with CHC1„ (3x50mL) . CHC1„ extracts were dried (MgSO, ) and concentrated to yellow oil. Chromatography on silica gel gave title compound, which was eluted with 10% MeOH-CHCl, and solidified to a yellow powder in CH,CN, Mp.138-140°C; 'H-NMR (DMS0-d 6 ) 8 ; 7.82 (S, 1, H-8) 6.46 (br S, 2, NH £ ) , 6.15 and 5.85 (both m, overlapping 5.90-5.70, m, total 4, 2',3' and cyclohexene CH-CH), 5.40 (m, 1, (H-N) , 4.90 (br m, 1, S-CH), 4.70 (t,J-5.3Hz, 1, 0H7 , 3 .45 (m, 2 , CH 2 -0) , 2.85 (br m, 1 , CH) , 2.70-2.55 (m, 1 , 0.5 CH 2 ) , 2 . 10- 1.50 (m, 7 , 3 CH 2 plus 0. 5 CH 2 ) Anal. calc. for C 17 H 21 5 0S: C.59.45; H.6.16; N.20.39; S.9.34 Found: C.59.17; H.6.18; N.20.31; S.9.25 Example 7 (±) -cis-4-(2-Amino-6-(2-cyclopenten-l-yl amino)-9H-purin-9-yl)-2- cvclopentene-1-methanol A solution of (+)-cis-4-(2-Amino-6-chloro-9H-purin-9-yl)-2-cyclopen- tene-1-methanol hydrate (0.53g, 1.87mMol) from Example 4, triethylamine (2.00g, 20mMol) and 3-amino cyclopentene hydrochloride (463mg, 3.87mMol) in lOmL of ethanol was stirred at reflux for 17 hours. The solution was allowed to cool to room temperature before the addition of 2mL of 1.0N NaOH. Concentration of the solution afforded the crude product which was purified by elution from a silica gel column using 5% methanol in chloroform (0.30g, 48.0%). Crystallization of such a sample from ethanol-acetonitrile gave an off-white powder, Mp.143-146°C; 'H-NMR Me 2 S0-d 6 ) 5 7.58 (s, 1H, purine H8), 6.97 (br d J=12Hz, 1H, NH), 6.10 (m, 1H, -CH) , 5.89-5.72 (m overlapping br s at 5.86, 5H, 3-CH, H_), 5.37 (m overlapping br m at 5.2; 4.73 (unresolved t, 1H, OH), 3.42 (m, 2H, 0CH 2 ) , 2.84 (br m, 1H, CH) 2.66-2.14 (m, overlapping DMS0, 3 x 0.5 CH 2 ), 1.80-1.48 (m, 2H, 2 x 0.5CH 2 ). Anal. calc. for c 16 H 2 o N 6° : c * 61 - 52 - H.6.45; N.26.9 Found: C.61.62; H.6.47; N.26.88. Example 8 (± -cis-4-r2-Amino-6-f fcis-3-(hydroxymethyl)-l-cyclopentyl]amino1 - 9H-purin-9-yl .-2-cyclopentene-l-methanol A solution of (+)-cis-4-(2-Amino-6-chloro-9H-purin-9-yl)-2-cyclopen- tene-1-methanol (530 mg, 2.00 mmol) from Example 4, 3-aminocyclo- pentyl-1-methanol (276 mg, 24 mmol), triethylamine (1.12 g, 10.98 mmol), and ethanol (20 mL) was stirred at reflux for 5 hours. An additional amount of triethylamine (1.17 g) was then added and the solution was refluxed for 8 additional hours. The solution was allowed to cool to room temperature and 2 mL of 1 N NaOH was added. The solution was concentrated and the residues were placed on silica gel column which was eluted with 10% methanol-chloroform (0.36 g, 52%). Recrystallization of such a sample from ethanol-acetonitrile gave title compound as white powder, m.p. 177-180 C. 'H-NMR (Me.SO-c ) δ 7.59 (s, 1H purine H.8), 7.06 (br s, 1H, NH) 6.12 __. b and 5.87 (m, 2H, HC=CH) 5.78 (br s, 2H, NH ) , 5.38 (br m, 1H, NCH, cyclopentene) 4.76 (t, J=5.3, OH cyclopentene) , 4.59 (t, J- 6.6, 1H, OH) 4.47 (br m, 1H, NCH), 3.44 (m, 2H, 0CH 2 cyclopentene), 3.35 (m, overlapping with H 2 0, 0CH„ cyclopentane) 2.87 (br m, 1H, CH cyclopen¬ tene), 2.58 (m, 1H 0.5 CH 2 cyclopentene), 2.05, 1.85, 1.68-1.43 and 1.25 (br m, total 8H, 3 CH_ cyclopentane, 1 CH cyclopentene, 0.52 CH. cyclopentene) . Anal. calc. for : C.59.29: H.7.02; N.24.40. Found: C.59.12; H.6.97; N.24.32. Example 9 (±)-cis-4- [2-Amino-6- ((8-Aminooctyl)amino)-9H-purin-9-yl)-2-cyclopen¬ tene-1-methanol A solution of (+)-(cj_s_)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopen- tene-1-methanol (272 mg, 1.00 mmol) from Example 4 and 1,8-diamino- octane (1.44 g, 10 mmol) in absolute ethanol (15 mL) was refluxed unde- nitrogen for 1.5 hours. The solution was concentrated, cooled, and the resulting precipitate filtered and crystallised from i-propanol to give title compound as white solid (160 mg, 42%), m.p. 125-127°C. ' H-NMR (DMSO-d, ) 8 7 . 57 (s , 1 , purine H- 8) , 7 .10 (br s , 1 , NH) , 6. 10 o and 5.85 (both m, 2, CH=CH) , 5.74 (br s, 1, NH 2 ) , 5.40 (m, 1, CH-N) , 4.75 (br , 1, OH), 3.7-3.0 (br m overlapped by H 2 0, CH 2 -0, 2NCH 2 , NH 2 ), 2.85 (br m, 1, H-4'), 2.7-2.4 (m overlapping d^DMSO, 0.5 CH 2 and CH CH N), 1.55 (m, 3.6, CH 2 CH 2 N and 0.5 CH 2 ) , 1.25 (br m, 8, 4CH 2 ). Anal. calc. for C 19 H 31 N 7 0.0.3H 2 0: C.60.23; H.8.41; N.25.88. Found: C,60.42; H.8.26; N.25.78. Example 10 (±)-cis-4-(2-Amino-6-((cvclopropylmethyl)amino")-9H-purin-9-yl)-2-cvclo- pentene-1-methanol (±)-(cis)- (2-Amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-methanol from Example 4 (0.544 g, 2 mmol), aminomethylcyclopropane hydrochloride (0.323 g, 3 mmol), triethylamine (0.607 g, 6 mmol) and methanol (15 mL) were heated in a Parr bomb for 12 hours. During this time, an additional arainomethylcyclopropane hydrochloride (0.108 g, 1 mmol) and triethylamine (0.101 g, 1 mmol), were added. 1 N NaOH (2 ml) was added and solution concentrated under vacuum, dried by evaporation of ethanol, and chromatographed on silica gel. Title compound was eluted in 5% methanol-chloroform; white powder after crystallisation from acetonitrile (0.425 g, 71%), m.p. 182-183°C. 'H-NMR (DMSO-d 6 ) δ 7.58 (s, 1, H-8), 6.10 and 5.85 (2 m, overlapping s at 5.77, total 4, CH=CH and NH ) , 5.40 (br m, 1, CH-N), 4.73 (t, J=5.3, 1, OH), 3.45 (m, 2, CH 2 -0), 3.40-3.20 (m, overlapping H 2 0, CH^NH) , 2.85 (br m, 1, CH) , 2.70-2.50 (m, overlapping solvent, 0.5 CH 2 ) , 1.70-1.50 (m, 1, 0.5 CH 2 , 1.20-1.0 (m, 1, CH-CH 2 NH) , 0.45-0.20 (m, 2, CH -CH cyclopropyl) . Anal. calc. for C^H^NgO: C.59.98; H.6.71; N.27.98. Found: C.59.90, 59,83; H.6.72, 6.76; N.27.91. Example A Tablet Formulations The following formulations A, β and C are prepared by wet granulation of the ingredients with a solution of povidone, followed by addition of magnesium stearate and compression. Formulation A (a) Active ingredient (b) Lactose B.P. (c) Povidone B.P. (d) Sodium Starch Glycollate (e) Magnesium Stearate Formulation B (a) Active ingredient (b) Lactose (c) Avicel PH 101 (d) Povidone B.P. (e) Sodium Starch Glycollate (f) Magnesium Stearate Formulation C mg/tablet Active ingredient 100 Lactose 200 Starch 50 Povidone 5 Magnesium stearate 4 359 The following formulations, D and E, are prepared by direct compression of the admixed ingredients. The lactose in formulation E is of the direct compression type (Dairy Crest - "Zeparox"). Formulation D mg/tablet Active ingredient 250 Pregelatinised Starch NF15 150 400 Formulation E m.E/tablet Active ingredient 250 Lactose 150 Avicel 100 500 Formulation F (Controlled Release Formulation-) The formulation is prepared by wet granulation of the ingredients (below) with a solution of povidone followed by the addition of magnesium stearate and compression. mp/tablet (a) Active ingredient 500 (b) Hydroxypropylmethylcellulose 112 (Methocel K4M Premium) (c) Lactose B.P. 53 (d) Povidone B.P. 28 (e) Magnesium Stearate 7 700 Drug release takes place over a period of about 6-8 hours and is complete after 12 hours. Example B Capsule Formulations Formulation A A capsule formulation is prepared by admixing the ingredients of Formulation D in Example A above and filling into a two-part hard gelatin capsule. Formulation B (infra) is prepared in a similar manner. Formulation B π-g/capsule (a) Active ingredient 250 (b) Lactose B.P. 143 (c) Sodium Starch Glycollate 25 (d) Magnesium Stearate 2 420 Formulation C mg/capsule (a) Active ingredient 250 (b) Macrogol 4000 B.P. 350 600 Capsules of formulation C are prepared by melting the Macrogol 4000 BP, dispersing the active ingredient in the melt and filling the melt into a two-part hard gelatin capsule. Formulation D mg/capsule Active ingredient 250 Lecithin 100 Arachis Oil 100 450 Capsules of formulation D are prepared by dispersing the active ingredient in the lecithin and arachis oil and filling the dispersion into soft, elastic gelatin capsules. Formulation E (Controlled Release Capsule) The following controlled release capsule formulation is prepared by extruding ingredients a, b and c using an extruder, followed by spheronisation of the extrudate and drying. The dried pellets are then coated with release- controlling membrane (d) and filled into a two-piece, hard gelatin capsule. mg/capsule (a) Active ingredient 250 (b) Microcrystalline Cellulose 125 (c) Lactose B.P. 125 (d) Ethyl Cellulose 13 513 Example C Injectable Formulation Formulation A Active ingredient 0.200g Hydrochloric acid solution, 0.1M, or Sodium hydroxide solution, 0.1M q.s. to pH 4.0 to 7.0 Sterile water q.s. to 10ml The active ingredient is dissolved in most of the water (35 -40 C) and the pH adjusted to between 4.0 and 7.0 with the hydrochloric acid or the sodium hydroxide as appropriate. The batch is then made up to volume with the water and filtered through a sterile micropore filter into a sterile 10ml amber glass vial (type 1) and sealed with sterile closures and overseals. Formulation B. Active ingredient 0.125 g Sterile, pyrogen-free, pH 7 phosphate buffer, q.s. to 25 ml Example D Intramuscular injection Active ingredient 0.20 g Benzyl Alcohol 0.10 g Glycofurol 75 1.45 g Water for Injection q.s. to 3.00 ml The active ingredient is dissolved in the glycofurol. The benzyl alcohol Is then added and dissolved, and water added to 3 ml. The mixture is then filtered through a sterile micropore filter and sealed in sterile 3 ml amber glass vials (type 1) . Example E Syrup Active ingredient 0.25 g Sorbitol Solution 1.50 g Glycerol 2.00 g Sodium Benzoate 0.005 g Flavour, Peach 17.42.3169 0.0125 ml Purified Water q.s. to 5.00 ml The active ingredient is dissolved in a mixture of the glycerol and most of the purified water. An aqueous solution of the sodium benzoate is then added to the solution, followed by addition of the sorbitol solution and finally the flavour. The volume is made up with purified water and mixed well. Example F Suppository mg/suppository Active ingredient (63μm)* 250 Hard Fat, BP (Witepsol H15 - Dynamit NoBel) 1770 2020 *The active ingredient is used as a powder wherein at least 90% of the particles are of 63μm diameter or less. One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45 C maximum. The active ingredient is sifted through a 200 m sieve and added to the molten Dase with mixing, using a silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45 C, the remaining Witepsol H15 is added to the suspension and stirred to ensure a homogenous mix. The entire suspension is passed through a 250 m stainless steel screen and, with continuous stirring, is allowed to cool to 40 C. At a temperature of 38 C to 40 C, 2.02g of the mixture is filled into suitable, 2 ml plastic moulds. The suppositories are allowed to cool to room temperature. Example G Pessaries mg/pessary Active ingredient (63μm) 250 Anhydrate Dextrose 380 Potato Starch 363 Magnesium Stearate 7 1000 The above ingredients are mixed directly and pessaries prepared by direct compression of the resulting mixture. Antiviral Activity The compounds are tested for anti-HIV activity in MT cells according to the method described by Averett, D.R. , Journal of Virological M Meetthods, 23, 1989, pp263-276. Activity is expressed as IC,.. values in μΑ. Determination of anti-HBV activity is carried out by testing the ability of a compound to prevent replication of duck HBV .in vitro, in the manner described by Tuttleman, Pugh and Summers (J. Virology. 58: 17-25, 1986). Duck hepatocytes are placed in culture, and infected with duck HBV. Three days after infection, the infected cells are exposed to various concentrations of the test compound for an additional period of eight days. After this exposure, DNA is extracted from each culture of infected cells and compound, and the amount of viral DNA is specifically determined and compared with that obtained from similar cultures lacking the test compound. Toxicity Data Determination of Growth Inhibition of Uninfected Mammalian Cells The capability of candidate compounds to inhibit the growth of D98 cells (human) and L cells (murine) is measured by determination of cell number following three days exposure of a standard number of cells to various dilutions of compound (Rideout, J.L., Krenitsky, T.A., Koszalka, G.W. , Cohn, N.K. , Chao, E.Y. Elion, G.B. , Latter, V.S., and Williams, R.B. (1982) J. Med. Chem. ___ : 1040-1044). The cell number is then compared to the number obtained in the absence of compound. Cell enumeration is performed by either direct particle counts following trypsinization of the monolaver, or by spectrophotometrie determination of the amount of vital stain taken up by the cells. Comparable results are obtained with both methods. Data Analysis The concentration of compound resulting in 50% of control values (IC j .-) is calculated either by direct interpolation from graphs of the log of the compound concentration versus the percent of control value, or from a computer program which analyses the data according to the same algorithm. Data in the range of 20% to 80% of control are used in these calculations. Compounds were tested in D98 cells and found to have an IC,- n value greater than lOOμM.

Claims: . CLAIMS A compound of formula (I): wherein R represents 2 2 R represents C „ cycloalkenyloxy; or R represents C, R cyclo- alkenylthio; or R represents an amino group which is mono substituted by any one of C. R branched or straight chain alkyl optionally substituted by one or more amino groups or alkylamino groups; C, Q cycloalkenyl; C. , hydroxyalkyl; C. , alkyl substi- j-o 1-b- l-o tuted by C_ _ cycloalkyl; or R represents an amino group which is di-substituted by any one substituent selected from C. „ branched or straight chain alkyl optionally substituted by one or more amino groups, alkylamino groups or C. alkoxy groups; C. „ 1-o 4-0 cycloalkenyl; C_. g hydroxyalkyl; C-_ 6 alkyl substituted by C_ R cycloalkyl and any one substituent selected from C , alkyl; C- hydroxyalkyl; C_ R cycloalkyl optionally substituted by C. - - - alkyl or aryl; aryl or aralkyl in which the aryl may optionally be substituted with C- , alkyl, hydroxy or halogen; allyl option- 3 ally subsituted with mono- or di-alkyl or alkoxy groups; and R represents hydrogen, amino, C fi alkyl, or thio optionally 1 3 substituted by C. , alkyl; provided that when R is A and R is hydrogen or C. alkyl, R is not an amino group substituted by a single C„ „ cycloalkyl and hydrogen or a branched or straight cchhaaiinn CC.. , alkyl; or a pharmaceutically acceptable derivative thereof. A compound of claim 1 wherein R is A. 3. A compound of claims 1 or 2 wherein the hydroxymethyl group is cis to the purine. 4. A compound selected from: (±)-cis-4-(2-Amino-6-(2-cyclohexen-l-yl)thio)-9H-purin-9-yl)-2- cyclopenten-1-methanol (±)-cis-4-(2-Amino-6-(2-cyclopenten-l-yl amino)-9H-purin-9-yl)-2- cyclopentene-1-methanol (±)-cis-4- [2-Amino-6-[ [cis-3-(hydroxymethyl)-1-cyclopentyl] - amino] -9H-purin-9-yl] -2-cyclopentene-l-methanol (±)-cis-4-[2-Amino-6-((8-Aminooctyl)amino)-9H-purin-9-yl)-2- cyclopentene-1-methanol (±)-cis-4-(2-Amino-6-((cyclopropylmethyl)amino)-9H-purin-9-yl)-2- cyclopentene-1-methano1 5. A compound of claim or any claim dependent thereon for use in medical therapy. S UB S TITUTESHEET 6. Use of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment or prophylaxis of a viral infection. 7. Use of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment or prophylaxis of a retroviral or a Hepatitis B viral infection. 8. Use of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment or prophylaxis of an HIV infection. 9. A process for the preparation of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable derivative thereof comprising: A) treating a compound of formula II (ID wherein R is as defined in claim 1 and Z represents a precursor 2 group for said R group with an agent or under conditions serving 2 to convert the precursor Z group to the desired R group; or Z represents a thio group onto which may be substituted an 2 appropriate group to form a compound of formula (I) wherein R is a substituted thio group; or B) reacting a compound of formula 1 2 (wherein R and R are as defined in claim 1 or a pharmaceuti¬ cally acceptable derivative thereof, with an agent serving to effect formation of the imidazole ring in the desired compound of formula (I) ; or i) where a compound of formula (I) is formed, converting the said compound to a pharmaceutically acceptable derivative thereof; or ii) where a pharmaceutically acceptable derivative of a compound of formula (I) is formed, converting the said derivative to the parent compound of formula (I) or to a further such derivative. 10. A pharmaceutical formulation comprising a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. SUBSTITUTE SHEET

Inventors: DALUGE SUSAN MARY, DALUGE, SUSAN, MARY
Applicants: WELLCOME FOUND, THE WELLCOME FOUNDATION LIMITED
Application year: 1990
Main classification: C07D473
IPC codes: A61K31, A61P31, C07D473